NCT06317558 Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy
| NCT ID | NCT06317558 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| Condition | NSCLC |
| Study Type | OBSERVATIONAL |
| Enrollment | 4,000 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2026-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 4,000 participants in total. It began in 2024-03-01 with a primary completion date of 2026-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to evaluate the efficacy and long-term clinical outcomes of different neoadjuvant immunotherapies in non-small cell lung cancer (NSCLC) patients using the real-world data. The main questions it aims to answer are: * What the best setting for immune checkpoint inhibitors as the neoadjuvant treatment? * How to determine the subgroups of patients benefit from neoadjuvant immunotherapy? Participants will receive neoadjuvant immunotherapy the study will analyze the real-world data.
Eligibility Criteria
Inclusion Criteria: 1. Histological diagnosis of non-small cell lung cancer (Stage I-IV, International Association for the Study of Lung Cancer staging eighth edition) 2. Patients who have previously undergone immune checkpoint inhibitors as the neoadjuvant treatment; 3. No previous history of malignant tumors and other malignant tumors at the same time, without any anti-tumor treatment; 4. Eastern Cooperative Oncology Group (ECOG) score 0-1, heart, lung, liver, brain and kidney function can tolerate surgery; 5. At least one measurable lesion (RECIST v1.1). Exclusion Criteria: 1. Patients included in unblinded clinical trials or anti-tumor drug intervention. 2. Radiotherapy or systemic therapy were used for NSCLC patients before the surgery.
Contact & Investigator
Shugeng Gao, MD
PRINCIPAL INVESTIGATOR
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Frequently Asked Questions
Who can join the NCT06317558 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying NSCLC. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06317558 currently recruiting?
Yes, NCT06317558 is actively recruiting participants. Contact the research team at gaoshugeng@cicams.ac.cn for enrollment information.
Where is the NCT06317558 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06317558 clinical trial?
NCT06317558 is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. The principal investigator is Shugeng Gao, MD at Cancer Institute and Hospital, Chinese Academy of Medical Sciences. The trial plans to enroll 4,000 participants.